Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3

Article View

Abstract
The Review of Diabetic Studies,2016,13,4,212-214.
Published:February 2017
Type:Letter to Editor
Authors:
Author(s) affiliations:

Yu-Hung Chang1, Der-Wei Hwu1,2, Wei-Pin Kao3, and Yau-Jiunn Lee1

1Lee’s Endocrinology Clinic, 130 Min-Tzu Rd, Pingtung 90000, TAIWAN.

2Graduate Institute of Clinical Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, TAIWAN.

3MoonCome Cardiovascular Clinic, 318 Heti Rd, Sanmin Dist., Kaohsiung City 80794, TAIWAN.

Abstract:

The use of commercialized statins in the prevention of cardiovascular diseases (CVD) has commonly been accepted based on the informative results of the Cholesterol Treatment Trialists (CTT) reports [1] As an additional effort in the prevention of CVD, professional societies have issued practical recommendations for healthcare providers on the effective use of statins in lowering low-density-lipoprotein cholesterol (LDL-C)[2]. Among these statins, atorvastatin and rosuvastatin are regarded as the most effective as they can reduce more than 30% of LDL-C, even at low doses (i.e. atorvastatin 10 mg; rosuvastatin 5 mg) [2]. The results of the recent HOPE-3 study [3], in which 10 mg rosuvastatin was found to reduce the development of CVD by 24% in intermediate-risk persons, may reinforce the role of rosuvastatin in CVD prevention. However, there are some concerns regarding the use of rosuvastatin.

Keywords:Nil